Opinion|Videos|August 1, 2024
ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.
Advertisement
Episodes in this series
- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
FDA OKs Pirtobrutinib in Frontline CLL/SLL
3
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
4
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
5